

Experience of MTZ Clinical Research in Bioequivalence studies

| Lp. | Therapeutic /Chemical subgroup | Chemical substance | Population |
|---|---|------------------------------------|---------------------------------|
| Alimentary tract and metabolism | | | |
| 1 | Drugs used in diabetes | Glimepiride | Healthy subjects |
| 2 | Lipid modifying agents | Lovastatin | Healthy subjects |
| 3 | Lipid modifying agents | Rosuvastatin | Healthy subjects |
| 4 | Lipid modifying agents | Rosuvastatin | Healthy subjects |
| 5 | Lipid modifying agents | Simvastatin | Healthy subjects |
| Antiinfectives for systemic use | | | |
| 6 | Antibacterials for systemic use | Azithromycin | Healthy subjects |
| 7 | Antibacterials for systemic use | Azithromycin | Healthy subjects |
| 8 | Antibacterials for systemic use | Azithromycin | Healthy subjects |
| 9 | Antivirals for systemic use | Oseltamivir | Healthy subjects |
| 10 | Antivirals for systemic use | Aciclovir | Healthy subjects |
| Antineoplastic and immunomodulating agents | | | |
| 11 | Antineoplastic agents | Capecitabine | Healthy subjects |
| 12 | Antineoplastic agents | Capecitabine | Metastatic Solid Tumors |
| 13 | Antineoplastic agents | Capecitabine | Metastatic Solid Tumors |
| 14 | Antineoplastic agents | Capecitabine | Healthy subjects |
| 15 | Antineoplastic agents | Capecitabine | Healthy subjects |
| 16 | Antineoplastic agents | Doxorubicin Hydrochloride Liposome | Advanced Carcinoma of the Ovary |
| 17 | Taxane | Paclitaxel | Metastatic breast cancer |
| Blood and blood forming organs | | | |
| 18 | Antithrombotic agents | Acetylsalicylic Acid | Healthy subjects |
| Cardiovascular system | | | |
| 19 | Agents acting on the renin-angiotensin system | Lisinopril | Healthy subjects |
| 20 | Agents acting on the renin-angiotensin system | Lisinopril | Healthy subjects |
| 21 | Agents acting on the renin-angiotensin system | Lisinopril | Healthy subjects |
| 22 | Calcium channel blockers | Nitrendypine | Healthy subjects |
| 23 | Calcium channel blockers | Nicardipine hydrochloride | Healthy subjects |
| 24 | Cardiac therapy | Isosorbide-5-mononitrate | Healthy subjects |
| 25 | Cardiac therapy | Isosorbide-5-mononitrate | Healthy subjects |
| 26 | Cardiac therapy | Isosorbide-5-mononitrate | Healthy subjects |
| 27 | Diuretics | Indapamide | Healthy subjects |
| 28 | Diuretics | Indapamide | Healthy subjects |
| 29 | Lipid modifying agents | Simvastatin | Healthy subjects |
| 30 | Vasoprotectives | Calcium dobesilate | Healthy subjects |

Experience of MTZ Clinical Research

Early Clinical Development

| Lp. | Therapeutic /Chemical subgroup | Chemical substance | Population |
|---|---|---|------------------|
| Dermatologicals | | | |
| 31 | Antipsoriatics | Tacalcitol | Plaque Psoriasis |
| 32 | Antipsoriatics | Tacalcitol | Plaque Psoriasis |
| 33 | Corticosteroids | Mometasone furoate | Healthy subjects |
| 34 | Corticosteroids | Mometasone furoate | Healthy subjects |
| 35 | Corticosteroids | Mometasone furoate | Healthy subjects |
| 36 | Corticosteroids | Mometasone furoate | Healthy subjects |
| 37 | Corticosteroids | Betamethasone dipropionate | Healthy subjects |
| 38 | | Betamethasone dipropionate and salicylic acid | Healthy subjects |
| 39 | Corticosteroids | Betamethasone dipropionate and salicylic acid | Healthy subjects |
| 40 | | Betamethasone dipropionate and gentamicin sulfate | Healthy subjects |
| 41 | Corticosteroids | Betamethasone dipropionate and gentamicin sulfate | Healthy subjects |
| 42 | Flavonoid | Genistein | Healthy subjects |
| Genito-urinary system and sex hormones | | | |
| 43 | Sex hormones and modulators of the genital system | Megestrol | Healthy subjects |
| 44 | Sex hormones and modulators of the genital system | Megestrol | Healthy subjects |
| Musculo-skeletal system | | | |
| 45 | Antiinflammatory and antirheumatic products | Ibuprofen | Healthy subjects |
| 46 | Antiinflammatory and antirheumatic products | Ibuprofen | Healthy subjects |
| 47 | Antiinflammatory and antirheumatic products | Ibuprofen | Healthy subjects |
| 48 | Anti-inflammatory and antirheumatic products | Ibuprofen | Healthy subjects |
| 49 | Antiinflammatory and antirheumatic products | Naproxen | Healthy subjects |
| 50 | Drugs for treatment of bone diseases | Alendronic acid | Healthy subjects |
| 51 | Drugs for treatment of bone diseases | Risedronic acid | Healthy subjects |
| 52 | Muscle relaxants | Thiocolchicoside | Healthy subjects |
| Nervous system | | | |
| 53 | Antiepileptics | Lamotrigine | Healthy subjects |
| 54 | Antiepileptics | Pregabalin | Healthy subjects |
| 55 | Antiepileptics | Topiramate | Healthy subjects |
| 56 | Antiepileptics | Topiramate | Healthy subjects |
| 57 | Antivertigo preparations | Cinnarazinum & Dimenhydrinatum | Healthy subjects |
| 58 | Other nervous system drugs | Betahistine | Healthy subjects |
| 59 | Psychoanaleptics | Amitriptyline | Healthy subjects |
| 60 | Psychoanaleptics | Amitriptyline | Healthy subjects |
| 61 | Psychoanaleptics | Aniracetam | Healthy subjects |
| 62 | Psychoanaleptics | Memantine | Healthy subjects |
| 63 | Psychoanaleptics | Mirtazapine | Healthy subjects |
| 64 | Psychoanaleptics | Rasagiline | Healthy subjects |

Date of issue: May 2019

MTZ Clinical Research Sp. z o.o.

Pawinskiego 5, 02-106 Warsaw, Poland

+48 22 572 59 59 +48 22 572 59 57

info@mtz-clinical.pl

mtz-clinical.pl

VAT N° PL 526 26 35 334

BUSINESS REGISTER N° 015209197

NATIONAL COURT REGISTER N° 0000129520

INITIAL CAPITAL: 208 500 PLN



Experience of MTZ Clinical Research

Early Clinical Development

| Lp. | Therapeutic /Chemical subgroup | Chemical substance | Population |
|-----|---------------------------------------|-------------------------------------|------------------|
| 65 | Psychoanaleptics | Trazodone | Healthy subjects |
| 66 | Psycholeptics | Olanzapine | Healthy subjects |
| | Respiratory system | | |
| 67 | Antihistamines | Clemastine | Healthy subjects |
| 68 | Antihistamines | Levocetirizine | Healthy subjects |
| 69 | Antihistamines | Loratadine | Healthy subjects |
| 70 | Drugs for obstructive airway diseases | Fluticasone propionate / salmeterol | Healthy subjects |
| 71 | Drugs for obstructive airway diseases | Mometasone furoate | Healthy subjects |
| 72 | Drugs for obstructive airway diseases | Mometasone furoate | Healthy subjects |
| 73 | Nasal preparations | Fluticasone furoate | Healthy subjects |
| | Various | | |
| 74 | Antiinflammatory / Sympathomimetics | Ibuprofen / Pseudoephedrine | Healthy subjects |
| 75 | Antiinflammatory / Sympathomimetics | Ibuprofen / Pseudoephedrine | Healthy subjects |

Date of issue: May 2019

MTZ Clinical Research Sp. z o.o.

Pawinskiego 5, 02-106 Warsaw, Poland

+48 22 572 59 59 +48 22 572 59 57

info@mtz-clinical.pl

mtz-clinical.pl

VAT N° PL 526 26 35 334

BUSINESS REGISTER N° 015209197

NATIONAL COURT REGISTER N° 0000129520

INITIAL CAPITAL: 208 500 PLN

